Immunovia AB is a diagnostic company with a mission to improve survival rates for pancreatic cancer patients through early detection. Immunovia focuses on developing and commercializing simple blood-based tests to identify proteins and antibodies that indicate that a high-risk individual has developed pancreatic cancer.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
